- Home
- DEVS vs BOLT Comparison
DEVS vs BOLT Comparison
Compare DEVS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- BOLT
- Stock Information
- Founded
- DEVS N/A
- BOLT 2015
- Country
- DEVS
- BOLT United States
- Employees
- DEVS N/A
- BOLT N/A
- Industry
- DEVS
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- BOLT Health Care
- Exchange
- DEVS NYSE
- BOLT Nasdaq
- Market Cap
- DEVS 30.1M
- BOLT 25.3M
- IPO Year
- DEVS N/A
- BOLT 2021
- Fundamental
- Price
- DEVS $0.72
- BOLT $0.56
- Analyst Decision
- DEVS
- BOLT Hold
- Analyst Count
- DEVS 0
- BOLT 5
- Target Price
- DEVS N/A
- BOLT $1.25
- AVG Volume (30 Days)
- DEVS N/A
- BOLT 126.9K
- Earning Date
- DEVS N/A
- BOLT 11-12-2024
- Dividend Yield
- DEVS N/A
- BOLT N/A
- EPS Growth
- DEVS N/A
- BOLT N/A
- EPS
- DEVS N/A
- BOLT N/A
- Revenue
- DEVS N/A
- BOLT $9,779,000.00
- Revenue This Year
- DEVS N/A
- BOLT $16.30
- Revenue Next Year
- DEVS N/A
- BOLT N/A
- P/E Ratio
- DEVS N/A
- BOLT N/A
- Revenue Growth
- DEVS N/A
- BOLT 35.86
- 52 Week Low
- DEVS N/A
- BOLT $0.55
- 52 Week High
- DEVS N/A
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- BOLT 28.96
- Support Level
- DEVS N/A
- BOLT $0.63
- Resistance Level
- DEVS N/A
- BOLT $0.69
- Average True Range (ATR)
- DEVS 0.00
- BOLT 0.03
- MACD
- DEVS 0.00
- BOLT -0.01
- Stochastic Oscillator
- DEVS 0.00
- BOLT 9.22
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.